{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prevention+of+Rejection+in+Kidney+Transplant", "query": { "condition": "Prevention of Rejection in Kidney Transplant" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 24, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prevention+of+Rejection+in+Kidney+Transplant&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-23T04:54:41.811Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05027906", "title": "Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prevention of Rejection in Kidney Transplant" ], "interventions": [ { "name": "AT-1501", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eledon Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 48, "start_date": "2022-02-18", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2025-06-29", "last_synced_at": "2026-07-23T04:54:41.811Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05027906" }, { "nct_id": "NCT00658359", "title": "Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplantation" ], "interventions": [ { "name": "Cyclosporine", "type": "DRUG" }, { "name": "CP-690,550", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 178, "start_date": "2008-08", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2018-02-23", "last_synced_at": "2026-07-23T04:54:41.811Z", "location_count": 37, "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00658359" }, { "nct_id": "NCT06126380", "title": "Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplant Rejection" ], "interventions": [ { "name": "AT-1501", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eledon Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 132, "start_date": "2023-10-25", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2025-12-10", "last_synced_at": "2026-07-23T04:54:41.811Z", "location_count": 26, "location_summary": "Los Angeles, California • Orange, California • Sacramento, California + 22 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06126380" }, { "nct_id": "NCT00817206", "title": "Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Renal Failure" ], "interventions": [ { "name": "LCP-Tacro", "type": "DRUG" }, { "name": "Prograf", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Veloxis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 326, "start_date": "2008-12", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2015-09-10", "last_synced_at": "2026-07-23T04:54:41.811Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00817206" }, { "nct_id": "NCT00483756", "title": "Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplantation" ], "interventions": [ { "name": "Cyclosporine", "type": "DRUG" }, { "name": "CP-690,550", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 338, "start_date": "2007-08", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2013-03-14", "last_synced_at": "2026-07-23T04:54:41.811Z", "location_count": 37, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 25 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00483756" }, { "nct_id": "NCT01095887", "title": "Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Kidney Transplant" ], "interventions": [ { "name": "Eculizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2010-05", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2015-07-20", "last_synced_at": "2026-07-23T04:54:41.811Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01095887" }, { "nct_id": "NCT00118742", "title": "Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Liver Transplantation" ], "interventions": [ { "name": "mycophenolate mofetil [CellCept]", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "18 Years to 74 Years" }, "enrollment_count": 293, "start_date": "2005-08", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2010-08-03", "last_synced_at": "2026-07-23T04:54:41.811Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00118742" }, { "nct_id": "NCT00363116", "title": "A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients" ], "interventions": [ { "name": "Daclizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 298, "start_date": "1999-04", "completion_date": "2004-12", "has_results": false, "last_update_posted_date": "2013-10-25", "last_synced_at": "2026-07-23T04:54:41.811Z", "location_count": 23, "location_summary": "Davis, California • Los Angeles, California • Washington D.C., District of Columbia + 19 more", "locations": [ { "city": "Davis", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00363116" }, { "nct_id": "NCT04046549", "title": "A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Allografts", "Rejection; Transplant, Kidney", "Transplant Rejection", "Kidney Transplantation" ], "interventions": [ { "name": "Belatacept", "type": "DRUG" }, { "name": "VIB4920", "type": "DRUG" }, { "name": "Thymoglobulin", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 25, "start_date": "2019-10-30", "completion_date": "2023-03-22", "has_results": true, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-07-23T04:54:41.811Z", "location_count": 4, "location_summary": "Los Angeles, California • San Francisco, California • Durham, North Carolina + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04046549" }, { "nct_id": "NCT00263328", "title": "Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplantation" ], "interventions": [ { "name": "Tacrolimus", "type": "DRUG" }, { "name": "CP-690,550", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 46, "start_date": "2005-12", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2015-07-13", "last_synced_at": "2026-07-23T04:54:41.811Z", "location_count": 27, "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00263328" } ] }